Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT07457502

Domestic Environmental Exposure and Progression of ILD: An Exploratory Case-Control Study

Sponsor: Ville de Paris

View on ClinicalTrials.gov

Summary

The project titled "Domestic Environmental Exposure and Progression of Progressive or Stable Fibrosing Interstitial Lung Diseases: An Exploratory Case-Control Study" is a Category 3 study involving 60 patients with progressive or stable fibrosing interstitial lung diseases (ILDs). These patients are matched based on the same ILD subtype and their use or non-use of antifibrotic medication. The study aims to thoroughly describe the domestic environment of these patients and investigate the associations between the progression of pulmonary fibrosis and: i) The presence of pollutants and risk factors in the home, including concentrations of nitrogen dioxide, volatile organic compounds, aldehydes, fine particles, mold, dust mite allergens, building defects, and lifestyle habits that increase pollutant exposure. ii) The ambient air quality at the patients' addresses. Occupational exposures will also be considered in the analysis. This project is designed to enhance our understanding of how an unfavorable domestic environment impacts the progression of pulmonary fibrosis and to evaluate the effects of the CMEI (Comprehensive Environmental and Indoor Audit) on patients' ability to manage identified risk factors within their homes, their respiratory health, and their medical diagnosis. The CMEI audit is a preventive measure that could serve as a significant intervention to alter patient behavior, reduce exposure, and improve health outcomes. This project is sponsored by the Environmental Health Laboratories Department, in collaboration with Unit 1018 of the Research Center in Epidemiology and Population Health (CESP), and two investigative centers: Tenon Hospital and Paris Saint-Joseph Hospital.

Official title: Domestic Environmental Exposure and Progression of Fibrosing Interstitial Lung Diseases: An Exploratory Case-Control Study

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

100

Start Date

2023-04-26

Completion Date

2026-10-26

Last Updated

2026-03-09

Healthy Volunteers

Conditions

Assess PID Diagnosis Revision After CMEI Audit Assess CMEI Recommendations' Impact on Respiratory Health ILD Progression and Exposure to Indoor Environnemental Risk ILD Progression and Exposure to Outdoor Polluants

Interventions

OTHER

Environmental audit of patient housing

During the home audit of the patient, the Environmental Health Medical Advisor searchs for potential sources of indoor pollution and other housing risk factors (building defects and occupant habits that negatively impact respiratory health). An environmental questionnaire is administered to the patient to gather information about the home environment (ventilation, presence of plants, presence of pets, pests, etc.) and the patient's lifestyle (ventilation habits, use of air fresheners and cleaning products, smoking, etc.). The home audit is conducted according to the principles of the NF X43-406 standard. During the home audit, direct measurements (TVOC index, particles, ambient parameters, cold surfaces) and standardized environmental samples (NO2, VOCs, aldehydes, mold, allergens) will be collected, followed by analysis in the SPSE. The outdoor polluants data concentration are recovred from the ambiant monitoring network at the patient's address by modeling.

Inclusion Criteria: * Patient aged over 18 years * Patient affected by one of the following interstitial lung diseases (ILDs): Idiopathic Pulmonary Fibrosis (IPF), Nonspecific Interstitial Pneumonia (NSIP), Pneumoconioses, ILDs associated with autoimmune features, Pleuroparenchymal Fibroelastosis (PPFE), Chronic Hypersensitivity Pneumonitis (CHP) whose etiology is not primarily related to the domestic environment, Stage 4 fibrosing sarcoidosis, unclassifiable ILDs. * ILD patient with progressive fibrosis over the past 12 months (case group) * ILD patient with non-progressive fibrosis over the past 12 months (control group) * Patients without reduction in the treatment of interstitial lung disease in the 12 months prior to inclusion, patients without treatment can be included * Matching "1 progressive fibrosis" / "2 non-progressive fibrosis": * Same ILD diagnosis * Use of antifibrotic treatment for both paired patients or absence of antifibrotic treatment for both paired patients * Both patients should preferably be matched within 3 months to limit significant contrasts in lifestyle and housing use related to the season * Patient who has received information about the protocol and does not object to participating * Patient affiliated with or beneficiary of a social security scheme or universal health coverage Exclusion Criteria: * Patient who has already received advice from a CMEI (Environmental and Occupational Medicine Consultation Center) in the past 12 months * Patient who has recently moved into their home (less than 1 year) * Patient living less than 6 months per year in the home to be investigated * Patient followed in psychiatry for a severe condition * Patient who does not speak French and is not accompanied by a person who shares their home and speaks French to act as a translator * Patient refusing to consent to participate in the research * Patient not living in Île-de-France * Patient with non-chronic Hypersensitivity Pneumonitis related to the domestic environment * Patient with sarcoidosis (except stage 4 fibrosing sarcoidosis) * Adult patient under legal protection and unable to give consent

Locations (2)

Hôpital Paris Saint Joseph

Paris, Paris, France

Hôpital de Tenon